Literature DB >> 8568305

A murine model of Candida glabrata vaginitis.

P L Fidel1, J L Cutright, L Tait, J D Sobel.   

Abstract

Vaginal Candida glabrata infections have increased significantly in recent years and are particularly common in women with uncontrolled diabetes mellitus. Efforts to understand the pathogenesis and treatment of this infection have been hindered by the lack of experimental animal models. Before onset of hyperglycemia, nonobese diabetic (NOD) mice inoculated intravaginally with clinical C. glabrata isolates were shown to support high vaginal titers of C. glabrata for > 14 days with evidence for superficial invasion of vaginal epithelial tissue. In contrast, congenic diabetic-resistant mice and mice susceptible to Candida albicans infections were significantly less susceptible to vaginal infection by C. glabrata, suggesting a potential link between the susceptibility of NOD mice to diabetes and their susceptibility to vaginal C. glabrata infections. This animal model of C. glabrata vaginitis provides a means to study the genetics and pathogenesis of C. glabrata infections and to evaluate the efficacy of antimycotic agents against C. glabrata.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8568305     DOI: 10.1093/infdis/173.2.425

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  39 in total

1.  Candida species differ in their interactions with immature human gastrointestinal epithelial cells.

Authors:  Christina Falgier; Sara Kegley; Heather Podgorski; Timothy Heisel; Kathleen Storey; Catherine M Bendel; Cheryl A Gale
Journal:  Pediatr Res       Date:  2011-05       Impact factor: 3.756

2.  Potent Antifungal Synergy of Phthalazinone and Isoquinolones with Azoles Against Candida albicans.

Authors:  Aaron D Mood; Ilandari Dewage Udara Anulal Premachandra; Stanley Hiew; Fuqiang Wang; Kevin A Scott; Nathan J Oldenhuis; Haoping Liu; David L Van Vranken
Journal:  ACS Med Chem Lett       Date:  2017-01-11       Impact factor: 4.345

Review 3.  Medically important bacterial-fungal interactions.

Authors:  Anton Y Peleg; Deborah A Hogan; Eleftherios Mylonakis
Journal:  Nat Rev Microbiol       Date:  2010-03-29       Impact factor: 60.633

4.  Antifungal Activity of Gepinacin Scaffold Glycosylphosphatidylinositol Anchor Biosynthesis Inhibitors with Improved Metabolic Stability.

Authors:  Sean D Liston; Luke Whitesell; Catherine A McLellan; Ralph Mazitschek; Vidmantas Petraitis; Ruta Petraitiene; Povilas Kavaliauskas; Thomas J Walsh; Leah E Cowen
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

5.  Protocols for vaginal inoculation and sample collection in the experimental mouse model of Candida vaginitis.

Authors:  Junko Yano; Paul L Fidel
Journal:  J Vis Exp       Date:  2011-12-08       Impact factor: 1.355

6.  Determination of MICING: a new assay for assessing minimal inhibitory concentration for invasive growth.

Authors:  J Zupan; Z Tomičić; P Raspor
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-27       Impact factor: 3.267

Review 7.  Cytokines in the host response to Candida vaginitis: Identifying a role for non-classical immune mediators, S100 alarmins.

Authors:  Junko Yano; Mairi C Noverr; Paul L Fidel
Journal:  Cytokine       Date:  2011-12-17       Impact factor: 3.861

8.  Risk factors for fluconazole-resistant Candida glabrata bloodstream infections.

Authors:  Ingi Lee; Neil O Fishman; Theoklis E Zaoutis; Knashawn H Morales; Mark G Weiner; Marie Synnestvedt; Irving Nachamkin; Ebbing Lautenbach
Journal:  Arch Intern Med       Date:  2009-02-23

9.  Role of glutathione in the oxidative stress response in the fungal pathogen Candida glabrata.

Authors:  Guadalupe Gutiérrez-Escobedo; Emmanuel Orta-Zavalza; Irene Castaño; Alejandro De Las Peñas
Journal:  Curr Genet       Date:  2013-03-01       Impact factor: 3.886

Review 10.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.